All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On Thursday 14 February 2019, a session on the use of chimeric antigen receptor-modified T (CAR T) cell therapy took place at the 1st European CAR T Cell Meeting, Paris, France. A talk was presented by Marie José Kersten, Department of Haematology, Academic Medical Center, Amsterdam, Netherlands, on when to use CAR T in lymphoma.
Professor Kersten began her talk by outlining the current treatment landscape of diffuse large B-cell lymphoma (DLBCL):
Then Professor Kersten continued her presentation by introducing the SCHOLAR-1 analysis by Michael Crump, from the Canadian Cancer Trials Group at Queen’s University, Kingston, Ontario, Canada, and colleagues. SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from two large randomized trials and two academic databases:
The SCHOLAR-1 analysis demonstrated consistent poor outcomes for patients with refractory non-Hodgkin lymphoma (NHL), and showed that effective treatments for refractory NHL represents a significant unmet need.
Professor Kersten then summarized how the treatment of B-cell malignancies has evolved in recent years and highlighted that adoptive immunotherapy with CAR T cells is a rapidly growing therapeutic approach to treating patients with B-cell malignancies.
Professor Kersten concluded her talk by stating that CAR T cell therapy in DLBCL has been shown to lead to durable remissions. Currently, there is no curative treatment option for this patient population and, thus, it is encouraging that real-world experiences showed that CAR T therapy is a feasible treatment option for patients with DLBCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox